Roche (RHHBY.US) submitted a PD-L1 inhibitor subcutaneous injection for marketing approval in China.

Market VisionFriday, Jul 26, 2024 11:30 pm ET

1min read

On July 27, the China National Medical Products Administration (NMPA) published on its website that the marketing application of Roche's (RHHBY.US) anti-PD-L1 monoclonal antibody (subcutaneous injection) has been accepted. According to the public information, the subcutaneous injection type of the product has been approved in many indications globally. The subcutaneous injection of atezolizumab can shorten the treatment time of each injection to 4-8 minutes (usually 7 minutes), while the standard intravenous infusion needs 30-60 minutes.

Atezolizumab (Tecentriq) is a monoclonal antibody targeting PD-L1 developed by Roche. It has been approved globally for the treatment of non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), urothelial carcinoma, metastatic triple-negative breast cancer (mTNBC) and multiple advanced solid tumors with BRAF V600 mutation. It has been approved for the treatment of extensive-stage small cell lung cancer in China in 2020.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.